Skip to content

A Pilot Randomized Clinical Trial of Mindfulness-Oriented Recovery Enhancement as an Adjunct to Methadone Treatment for People with Opioid Use Disorder and Chronic Pain: Impact on Illicit Drug Use, Health, and Well-Being

Nina A Cooperman, Adam W. Hanley, Anna Kline, E. Garland

Journal of Substance Abuse Treatment May 8, 2021 DOI: 10.1016/j.jsat.2021.108468 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial Peer reviewed
Sample size 30
Population Individuals in methadone maintenance treatment for opioid use disorder
Intervention Mindfulness-Oriented Recovery Enhancement (MORE)
Duration 8-week intervention, 16-week follow-up
Topics Addiction Meditation
Key findings MORE plus MMT reduced illicit drug use, craving, pain, depression, and anxiety, and improved well-being, vitality, and social functioning through 16-week follow-up compared to MMT alone.

Abstract

Background: Chronic pain is highly prevalent among people in methadone maintenance treatment (MMT) for opioid use disorder and is known to be an important contributor to treatment discontinuation and opioid relapse. Mindfulness-Oriented Recovery Enhancement (MORE) is one of the few interventions developed and tested as an integrated treatment to simultaneously address both pain and illicit opioid use; however, this study is the first to evaluate MORE as an adjunct to MMT.

Methods: Randomized individuals in MMT (N=30) received MORE plus methadone TAU (n=15) or methadone TAU, only (n=15). Participants in the MORE arm received their MMT, as usual, and attended eight, weekly, two-hour MORE groups at their MMT clinics. Participants in the TAU arm received their MMT, as usual, and group or individual counseling, as required by the clinic. TAU counseling consisted of relapse prevention, cognitive-behavioral therapy, and supportive treatment. TAU participants did not receive any mindfulness-based intervention. Participants completed assessments at baseline, post-treatment (i.e., 8-weeks post-baseline), and follow-up (i.e., 16-weeks post-baseline).

Results: Participants in MORE evidenced significantly fewer baseline adjusted days of illicit drug use and significantly lower levels of craving through 16-week follow-up compared to TAU. Also, participants in MORE reported significantly lower levels of pain, physical and emotional limitations, depression, and anxiety through 16-week follow-up compared to TAU. Conversely, participants in MORE reported significantly higher levels of well-being, vitality, and social functioning through 16-week follow-up compared to TAU.

Conclusion: MORE could be an effective adjunct to MMT, and larger trials are warranted.

Comparable studies

Other randomized controlled trials on addiction, most cited first.

Study Year Design Participants
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder Adults aged 25–65 with DSM-IV alcohol dependence and at least 4 heavy drinking days in... 2022 Randomized controlled trial n = 95
Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. Detoxified heroin-addicted patients 2002 Randomized controlled trial n = 70
A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial. Adults with alcohol dependence engaged in motivational enhancement therapy 2019 Randomized controlled trial n = 40
A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial. Cocaine-dependent adults 2019 Randomized controlled trial n = 55
Single Versus Repeated Sessions of Ketamine-Assisted Psychotherapy for People with Heroin Dependence Detoxified inpatients with heroin dependence 2007 Randomized controlled trial n = 59

Citations in the library

Cited by 19

and 14 more in the library

Cites 8

and 3 more in the library

Explore topics